A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
A phase 1/2 trial of Trastuzumab rezetecan, Carboplatin, Bevacizumab in ovarian cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer is a phase 1/2 interventional study registered as NCT06840002 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 150 participants planned, started 2025-03-18 and due to reach its primary completion in 2026-12. Interventions recorded: SHR-A1811, Carboplatin, Bevacizumab, Oxaliplatin for Injection, Paclitaxel injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal
Shares Trastuzumab rezetecan, CAPOX (capecitabine, oxaliplatin), Jiangsu Hengrui Pharmaceuticals, Bevacizumab.
- TrialA Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialA Study of SHR-A1811 in Subjects With Ovarian Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialSHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Bevacizumab, Carboplatin.
- TrialA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.